Trials
Search / Trial NCT05652569

CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

Launched by GERMAN CANCER RESEARCH CENTER · Dec 7, 2022

Trial Information

Current as of January 16, 2025

Recruiting

Keywords

Metastatic Breast Cancer Stage Iv Breast Cancer Precision Oncology Genomics Guided Biomarker Stratification Personalized Oncology Genomic Profiling

ClinConnect Summary

The CATCH trial is studying how to use genetic information to improve treatment for patients with metastatic breast cancer, which is breast cancer that has spread to other parts of the body. The main goal is to find specific markers in patients' tumors that can help doctors choose the best targeted therapies for their individual cases. This means that instead of a one-size-fits-all approach, treatments can be tailored to the unique characteristics of each patient's cancer.

To participate in the trial, you need to be at least 18 years old and diagnosed with advanced or metastatic breast cancer, regardless of the specific type or how many treatments you have already received. During the trial, doctors will collect samples from your cancer and blood to analyze them for genetic information. This will help identify potential treatments that might work best for you. The trial is currently recruiting participants, and it's important to know that if you decide to join, you will be contributing to valuable research that aims to improve future therapies for breast cancer patients.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Female and male breast cancer patients ≥ 18 or if the legal guardian has agreed to the respective informed consent form (ICF)
  • Patients with advanced or metastatic breast cancer (irrespective of clinical parameters such as TNM, subgroups, therapy lines)
  • Patients, who agreed to and were able to sign the informed consent form.
  • Exclusion Criteria:
  • Early breast cancer
  • Inability to take a tissue bioptic sample due to reasons such as physical location of the lesion or health of the patient
  • Any physical or mental handicap or severe comorbidities that would hamper the adequate cooperation with the patient.

Trial Officials

Andreas Schneeweiss, MD

Principal Investigator

National Center for Tumor Diseases, Heidelberg

Peter Lichter, PhD

Principal Investigator

German Cancer Research Center

Verena Thewes, PhD

Principal Investigator

National Center for Tumor Diseases, Heidelberg

About German Cancer Research Center

The German Cancer Research Center (DKFZ) is a leading biomedical research institution dedicated to advancing cancer research and its application in clinical settings. Located in Heidelberg, DKFZ conducts innovative studies aimed at understanding the complexities of cancer biology, developing novel therapeutic strategies, and improving patient outcomes. As a prominent clinical trial sponsor, the center collaborates with national and international partners to facilitate cutting-edge research, translating scientific discoveries into effective treatments. With a commitment to excellence and a multidisciplinary approach, DKFZ plays a pivotal role in the global fight against cancer.

Locations

Erlangen, , Germany

Augsburg, , Germany

Tübingen, , Germany

Essen, , Germany

Berlin, , Germany

Ulm, , Germany

Würzburg, , Germany

Heidelberg, , Germany

Köln, , Germany

Dresden, , Germany

Regensburg, , Germany

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials